Practical Recommendations and New Therapies for Wilson’s Disease

Drugs

Volumn 50, Issue 2, 1995, Pages 240-249

  Brewer, George J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; COPPER; CORTICOSTEROID; METALLOTHIONEIN; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRIENTINE; ZINC;

BEHAVIOR DISORDER; BILE; BONE MARROW DEPRESSION; CHELATION; COPPER BLOOD LEVEL; COPPER METABOLISM; DRUG EFFICACY; DRUG MECHANISM; EARLY DIAGNOSIS; FEVER; GENETIC SCREENING; HUMAN; LIVER BIOPSY; LIVER DISEASE; LIVER METABOLISM; LYMPHADENOPATHY; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; PROGNOSIS; RASH; REVIEW; SLIT LAMP; STOMACH PAIN; URINALYSIS; WILSON DISEASE;

CHELATING AGENTS; COPPER; FEMALE; HEPATOLENTICULAR DEGENERATION; HUMAN; LIVER; METALLOTHIONEIN; MOLYBDENUM; PENICILLAMINE; PREGNANCY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRIETHYLENETETRAMINE; ZINC;

EID: 0029120836     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199550020-00004     Document Type: Article

References (46)

1. Wilson Disease
2. Wilson’s disease
3. Disorders of copper transport
4. Copper metabolism in normal subjects
5. Defective biliary excretion of copper in Wilson’s disease
6. Biliary excretion of copper in Wilson’s disease
7. Clinical assessment of 31 patients with Wilson’s disease: correlations with structural changes on magnetic resonance imaging
8. The psychiatric presentations of Wilson’s disease
9. Does a vegetarian diet control Wilson’s disease?
10. The Wilson’s disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene
11. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene
12. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson’s disease
13. The treatment of Wilson’s disease with zinc: IV. Efficacy monitoring using urine and plasma copper
14. Penicillamine. A new oral therapy for Wilson’s disease
15. Treatment of Wilson’s disease with trientine (tri-ethylene tetramine) dihydrochloride
16. The treatment of Wilson’s disease with zinc: X. Intestinal metallothionein induction
17. Oral zinc therapy for Wilson’s disease
18. Treatment of Wilson’s disease with zinc: 1. Oral zinc therapy regimens
19. Zinc therapy of Wilson’s disease: VIII. Dose response studies
20. Initial therapy of Wilson’s disease patients with tetrathiomolybdate
21. Treatment of Wilson’s disease with tetrathiomolybdate: I. Initial therapy in 17 neurologically affected patients
22. Worsening of neurologic syndrome in patients with Wilson’s disease with initial penicillamine therapy
23. Wilson’s disease: clinical presentation and use of prognostic index
24. 64copper uptake with copper balance
25. Treatment of Wilson’s disease with zinc: III. Prevention of reaccumulation of hepatic copper
26. Treatment of Wilson’s disease
27. Treatment of Wilson’s disease with zinc: V. Changes in serum levels of lipase, amylase and alkaline phosphatase in Wilson’s disease patients
28. The treatment of Wilson’s disease with zinc: VI. Initial treatment studies
29. The treatment of Wilson’s disease with zinc: VII. Protection of the liver from copper toxicity by zinc induced metallothionein in a rat model
30. Zinc therapy of Wilson’s disease: VIII. Dose response studies
31. The treatment of Wilson’s disease with zinc: IX. Response of serum lipids
32. Treatment of Wilson’s disease with zinc: XI. Interaction with other anti-copper agents
33. Treatment of Wilson’s disease with zinc: XII. Dose regimen requirements
34. Treatment of Wilson’s disease with zinc: XIII. Therapy with zinc in presymptomatic patients from the time of diagnosis
35. Oral zinc sulfate as long-term treatment in Wilson’s disease (hepatolenticular degeneration)
36. Oral zinc in Wilson’s disease
37. Management of Wilson’s disease with zinc sulfate: experience in a series of 27 patients
38. Congenital connective tissue defect probably due to D-penicillamine treatment in pregnancy
39. Neonatal abnormalities associated with D-penicillamine treatment during pregnancy
40. Teratogenic effect of copper deficiency and excess
41. Reversible pancytopenia secondary to treatment with tetrathiomolybdate
42. Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats
43. Copper metabolism in rats given Di- or trithiomolybdates
44. Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate
45. An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep